Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giada Bianchi

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
Transplantation and Cellular Therapy|May 23, 2022
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple MyelomaSarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple MyelomaGüllü Görgün, Mehmet K Samur, Kristen B Cowens, et al.
Leukemia|May 12, 2018
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencingGuangwu Guo, Noopur S Raje, Charles Seifer, et al.
Blood|June 10, 2025
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironmentNicolas A Gort-Freitas, Maria Moscvin, Matteo Claudio Da Viá, et al.
American Journal of Hematology|November 12, 2025
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL AmyloidosisMatthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, et al.
Nature Methods|December 5, 2024
The dynamics of hematopoiesis over the human lifespanHojun Li, Parker Côté, Michael Kuoch, et al.
Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
Transplantation and Cellular Therapy|May 23, 2022
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple MyelomaSarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple MyelomaGüllü Görgün, Mehmet K Samur, Kristen B Cowens, et al.
Leukemia|May 12, 2018
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencingGuangwu Guo, Noopur S Raje, Charles Seifer, et al.
Blood|June 10, 2025
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironmentNicolas A Gort-Freitas, Maria Moscvin, Matteo Claudio Da Viá, et al.
American Journal of Hematology|November 12, 2025
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL AmyloidosisMatthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, et al.
Nature Methods|December 5, 2024
The dynamics of hematopoiesis over the human lifespanHojun Li, Parker Côté, Michael Kuoch, et al.
Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Pageof 10